Using proteomic profiling to characterize protein signatures of different thymoma subtypes

• Main Authors: Liang-Chuan Lai, Qiang-Ling Sun, Yu-An Chen, Yi-Wen Hsiao, Tzu-Pin Lu, Mong-Hsun Tsai, Lei Zhu, Eric Y. Chuang, Wentao Fang
• Format: Article
• Language: English
• Published: BMC 2019-08-01
• Series: BMC Cancer
• Subjects: Proteomic profiling; Thymoma; Support vector machine; WHO classification
• Online Access: http://link.springer.com/article/10.1186/s12885-019-6023-4

Abstract Background Histology is a traditional way to classify subtypes of thymoma, because of low cost and convenience. Yet, due to the diverse morphology of thymoma, this method increases the complexity of histopathologic classification, and requires experienced experts to perform correct diagnosis. Therefore, in this study, we developed an alternative method by identifying protein biomarkers in order to assist clinical practitioners to make right classification of thymoma subtypes. Methods In total, 204 differentially expressed proteins in three subtypes of thymoma, AB, B2, and B3, were identified using mass spectrometry. Pathway analysis showed that the differentially expressed proteins in the three subtypes were involved in activation-related, signaling transduction-related and complement system-related pathways. To predict the subtypes of thymoma using the identified protein signatures, a support vector machine algorithm was used. Leave-one-out cross validation methods and receiver operating characteristic analysis were used to evaluate the predictive performance. Results The mean accuracy rates were > 80% and areas under the curve were ≧0.93 across these three subtypes. Especially, subtype B3 had the highest accuracy rate (96%) and subtype AB had the greatest area under the curve (0.99). One of the differentially expressed proteins COL17A2 was further validated using immunohistochemistry. Conclusions In summary, we identified specific protein signatures for accurately classifying subtypes of thymoma, which could facilitate accurate diagnosis of thymoma patients.